Navigation Links
Daiichi Sankyo, Virtici and Celdara Medical Announce Collaboration to Identify and Progress High Potential Therapeutics

TOKYO, SEATTLE, and LEBANON, N.H., Jan. 8, 2014 /PRNewswire/ -- Daiichi Sankyo, Co., Ltd., Virtici, LLC and Celdara Medical, LLC announced today that they have entered into a collaboration to jointly investigate novel therapeutic candidates and thereby further strengthen the Daiichi Sankyo developmental pipeline across multiple therapeutic areas.

Virtici and Celdara Medical are affiliated, independent companies that build and develop pipelines of high potential therapeutic assets.  The collaboration is intended to accelerate the time from discovery to development with the potential to deliver first-in-class treatments that address significant unmet medical needs.  Funding is channeled into the most promising targets to drive early research before moving into larger scale clinical development. 

"This collaboration strengthens our ability to access potential breakthrough innovation, and demonstrates our continued commitment to working with partners at the forefront of science," said Mahmoud Ghazzi, M.D., Ph.D., Global Head of Development, Daiichi Sankyo, Co. Ltd.  "By augmenting in-house research and other development avenues, these focused, exclusive, indication-targeted partnerships can accelerate medical innovations into the clinic and ultimately to patients."

"We are extremely pleased to be working with Daiichi Sankyo," said Neil Fanger, Ph.D., President and Chief Executive Officer of Virtici. "Using our unique model, infrastructure and capabilities, we can help further advance Daiichi Sankyo's strong track record of innovative drug development. This collaboration leverages the complementary capabilities and synergies between our firms."

"This alliance represents a new partnership paradigm for Virtici and Celdara Medical while validating our underlying development model. Daiichi Sankyo's impressive capabilities, global reach, and open, collaborative culture make them ideal partners," said Jake Reder, Ph.D., President and Chief Executive Officer of Celdara Medical. "The team at Celdara Medical is excited to work hand-in-hand with Daiichi Sankyo on some of the most challenging problems in human health."

About Daiichi Sankyo

The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimize growth opportunities across the value chain. For more information about Daiichi Sankyo, please visit   

About Virtici, LLC

Founded in 2011, Virtici is a privately held product-development company headquartered in Seattle, Washington. Virtici's mission is to improve quality of life and save lives, and is primarily developing products to improve the way we diagnose and treat cancer, autoimmunity, and cardiovascular/metabolic diseases. Virtici, working closely with our affiliate Celdara Medical, partners with inventors and their research institutions, bringing the business and finance expertise to accelerate product development. Working with its partners in the pharmaceutical industry, Virtici connects the entire product development lifecycle by improving innovation, enhancing discovery and increasing product development efficiencies. For more information about Virtici, please visit

About Celdara Medical, LLC

Celdara Medical was founded by Drs. Jake Reder and Michael Fanger in 2008, and is headquartered at the Dartmouth Regional Technology Center (DRTC) in Lebanon, NH. Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. Celdara Medical, working closely with our affiliate Virtici, partners with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery and profitability. With robust funding options, a diverse and high impact Programmatic pipeline, and partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health. For more information about Celdara Medical, please visit

SOURCE Daiichi Sankyo, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Daiichi Sankyo Submits Edoxaban Marketing Authorization Application to the EMA for Once-Daily Use for Stroke Prevention in Atrial Fibrillation and for the Treatment and Prevention of Recurrence of Venous Thromboembolism
2. Daiichi Sankyos Once-Daily Edoxaban Meets Primary Efficacy Endpoint for Stroke Prevention and Superiority for the Principal Safety Endpoint Compared to Warfarin for Patients with Atrial Fibrillation in a Phase 3 Clinical Trial
3. Daiichi Sankyos Once-Daily Edoxaban Shows Comparable Efficacy and Superiority for the Principal Safety Endpoint Compared to Warfarin in a Phase 3 Study for the Treatment of Symptomatic VTE and Prevention of its Recurrence
4. Daiichi Sankyo CEO John Gargiulo Elected as National Pharmaceutical Councils Chairman of the Board
5. Daiichi Sankyo ha completato larruolamento dei pazienti per lo studio Hokusai-VTE su Edoxaban, il più ampio trial clinico di fase 3 per il trattamento delle tromboembolie venose ricorrenti
6. Daiichi Sankyo Completes Enrolment in Hokusai - VTE, investigating once-daily Edoxaban in the Largest Single Phase 3 Study for the Treatment and Prevention of Recurrence of VTE
7. Daiichi Sankyo, Inc. Receives FDA Approval to Package Product at New Facility in Bethlehem, PA
8. Kalila Medical Announces CE Mark Approval For The Vado Steerable Sheath Used During Atrial Fibrillation Procedures
9. Puritan Medical Products erhält zwei neue Patente für beflockte Tupfer in Japan
10. Agile Therapeutics Appoints Dr. Elizabeth Ijeoma Onyemelukwe Garner as Chief Medical Officer
11. Ensil Canada is Launching a New Medical Device: Publicly Traded Companies Are Invited to Acquire This Technology or Partner with Ensil Canada on the Marketing and Distribution of This New Device
Post Your Comments:
(Date:11/26/2015)... 26, 2015 ... of the  "2016 Future Horizons and ... Drug Monitoring (TDM) Market: Supplier Shares, ... Opportunities"  report to their offering.  ... the addition of the  "2016 Future ...
(Date:11/26/2015)... 26, 2015 Research and Markets ( ... "2016 Future Horizons and Growth Strategies in ... Shares, Country Segment Forecasts, Competitive Intelligence, Emerging Opportunities" ... --> --> This new ... Italian therapeutic drug monitoring market, including emerging tests, ...
(Date:11/25/2015)... , Nov. 25, 2015 ... addition of the "Global Brain Monitoring ... offering. --> ) has ... Brain Monitoring Devices Market 2015-2019" report ... and Markets ( ) has announced ...
Breaking Medicine Technology:
(Date:11/27/2015)... ... 2015 , ... The moment you stop improving is the ... the needs of advisers and clients but going above and beyond to find ... service. However, there's always room for improvement, which is why the entire Consulting ...
(Date:11/27/2015)... ... November 27, 2015 , ... ... successful and prominent nonprofit healthcare organizations in the country. They have overseen financial ... organizations, and helped advance the healthcare industry as a whole through their advocacy ...
(Date:11/27/2015)... ... November 27, 2015 , ... Indosoft Inc., ... the incorporation of Asterisk 11 LTS (Long Term Support) into its Q-Suite 5.10 ... brings Q-Suite 5.10 up-to-date with a version of Asterisk that will receive not ...
(Date:11/26/2015)... ... November 26, 2015 , ... CognisantMD and Cambridge Memorial ... in the Waterloo region. Using the Ocean Platform, family physicians can now order ... electronic medical record (EMR) without the need for redundant patient entry or an ...
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Jobs in ... by healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... the month of October 2015 among those searching for healthcare jobs through the company’s ...
Breaking Medicine News(10 mins):